Well done Arron and team18 Aug 2025 07:15
London South East
Share PricesAptamer Group Share PriceAptamer Group Share Regulatory NewsContract extension with global pharma partner
Pinned to quick picksAptamer Group Regulatory News (APTA)
APTA Share Price
APTA Share
Price
APTA Share News
APTA Share
News
APTA Share Chat
APTA Share
Chat
APTA Share Trades
APTA Share
Trades
APTA Live RNS
APTA
Live RNS
1
Aptamer Group Information
Add APTA to Timeline
Remove APTA from Timeline
Add APTA to Watchlist
Add APTA to Watchlist
Add APTA to Alert
Add APTA to Alert
Buy APTA Shares
Buy APTA Shares
Share Price Information for Aptamer Group (APTA)
London Stock Exchange
Share Price:
0.685
Bid:
0.00
Ask:
0.00
Change:
0.00 (0.00%)
Spread: 0.00 (0.00%)Open: 0.00High: 0.00Low: 0.00Prev. Close: 0.685
APTA Live PriceLast checked at 07:13:24
Contract extension with global pharma partner
Today 07:00
RNS Number : 6181V
Aptamer Group PLC
18 August 2025
18 August 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Contract extension and new work order with top 5 global pharma partner Follow-on agreement advances Optimer® binders into a fully functional ELISA assay, retaining IP for future licensing opportunities
Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce a contract extension, entailing a new work order, with a top 5 global pharmaceutical company.
As previously announced in the Company's commercial trading update on 6 November 2024, following the successful completion of a project for the development of Optimer® binders to support an ELISA assay, Aptamer has now secured an extension to this project.
This paid-for extension involves the conversion of these binders into a fully functional ELISA assay. This progression demonstrates the efficacy of Aptamer's Optimer® technology in meeting the partner's requirements and advances the project into assay development.
Aptamer retains ownership of the intellectual property associated with these binders, positioning the Company to potentially establish commercialisation licenses in the future. This extension underscores the Group's ability to deliver high-quality results that foster ongoing partnerships with leading pharmaceutical companies.
Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: "We are delighted to have successfully completed the initial binder development phase for this top 5 pharma partner and to now extend our collaboration into assay conversion.
This milestone not only validates the performance of our Optimer® platform but also highlights its potential for broader applications in diagnostics and therapeutics. Retaining IP ownership provides us with opportunities for future licensing revenues, aligning with our strategy to build long-term value through repeat business and commercialis